Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) Return on Equity: 2022-2024

  • Summit Therapeutics' Return on Equity rose 62.00% to -0.44% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.44%, marking a year-over-year increase of 62.00%. This contributed to the annual value of -1.01% for FY2024, which is 501.00% up from last year.
  • Per Summit Therapeutics' latest filing, its Return on Equity stood at -0.44% for Q4 2024, which was down 1.75% from -0.44% recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Return on Equity registered a high of -0.26% during Q3 2022, and its lowest value of -1.06% during Q4 2023.
  • Over the past 3 years, Summit Therapeutics' median Return on Equity value was -0.44% (recorded in 2024), while the average stood at -0.51%.
  • In the last 5 years, Summit Therapeutics' Return on Equity slumped by 78bps in 2023 and then skyrocketed by 62bps in 2024.
  • Over the past 3 years, Summit Therapeutics' Return on Equity (Quarterly) stood at -0.28% in 2022, then plummeted by 78bps to -1.06% in 2023, then soared by 62bps to -0.44% in 2024.
  • Its last three reported values are -0.44% in Q4 2024, -0.44% for Q3 2024, and -1.06% during Q4 2023.